- Home
- SST vs EPIX Comparison
SST vs EPIX Comparison
Compare SST & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- EPIX
- Stock Information
- Founded
- SST 2013
- EPIX 2009
- Country
- SST United States
- EPIX Canada
- Employees
- SST N/A
- EPIX N/A
- Industry
- SST Diversified Commercial Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- EPIX Health Care
- Exchange
- SST Nasdaq
- EPIX Nasdaq
- Market Cap
- SST 67.8M
- EPIX 76.8M
- IPO Year
- SST N/A
- EPIX N/A
- Fundamental
- Price
- SST $0.46
- EPIX $1.63
- Analyst Decision
- SST Buy
- EPIX Hold
- Analyst Count
- SST 2
- EPIX 3
- Target Price
- SST $3.50
- EPIX $2.00
- AVG Volume (30 Days)
- SST 144.3K
- EPIX 172.2K
- Earning Date
- SST 03-10-2025
- EPIX 02-11-2025
- Dividend Yield
- SST N/A
- EPIX N/A
- EPS Growth
- SST N/A
- EPIX N/A
- EPS
- SST N/A
- EPIX N/A
- Revenue
- SST $343,925,000.00
- EPIX N/A
- Revenue This Year
- SST $8.34
- EPIX N/A
- Revenue Next Year
- SST N/A
- EPIX N/A
- P/E Ratio
- SST N/A
- EPIX N/A
- Revenue Growth
- SST N/A
- EPIX N/A
- 52 Week Low
- SST $0.42
- EPIX $1.40
- 52 Week High
- SST $2.73
- EPIX $9.60
- Technical
- Relative Strength Index (RSI)
- SST 34.30
- EPIX 40.19
- Support Level
- SST $0.45
- EPIX $1.62
- Resistance Level
- SST $0.58
- EPIX $1.70
- Average True Range (ATR)
- SST 0.06
- EPIX 0.05
- MACD
- SST -0.00
- EPIX -0.00
- Stochastic Oscillator
- SST 14.59
- EPIX 20.00
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.